BioCryst Pharmaceuticals | Capitale Ordinario





Capitale Ordinario Cambiamento Data
Alnylam Pharmaceuticals USD 131.79M 130.49M 2025-09
BioCryst Pharmaceuticals USD 1.9M 3K 2023-09
Chugai Pharma JPY 1.65B 8K 2025-12
Daiichi Sankyo JPY 1.85B 9K 2025-12
DBV Technologies USD 11.65M 1000 2025-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 0 2025-09
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Glaxosmithkline GBP 4.03B 2.68B 2025-09
Incyte USD 196.13M 2.01M 2025-09
Ionis Pharmaceuticals USD 161.14M 160.98M 2025-09
Karyopharm Therapeutics USD 13K 0 2024-09
Neurocrine Biosciences USD 99.7M 700K 2025-09
Novavax USD 1.62M 211K 2024-09
PTC Therapeutics USD 79.93M 554K 2025-09
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 104.77M 7.06M 2025-09
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Vertex Pharmaceuticals USD 254M 2.29M 2025-09


BioCryst Pharmaceuticals Capitale Ordinario - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.